CompletedNCT02013531
Brexpiprazole Added to Antidepressants for Depression With Anxiety Symptoms
About this title
Read the official source — NCT02013531Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Tuscon and 20 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateNovember 2013
- Recruitment status
- Completed
- Enrollment listed in the registry
- 37
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT02013531
- Official title
Show the full official title
Protocol 331-13-002: An Exploratory, Multicenter, Open-label, Flexible-dose Trial of Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Tuscon · Garden Grove · Oceanside
18 more locations
- Temecula
- Gainesville
- Jacksonville
- Miami
- Atlanta
- Lafayette
- Baltimore
- Boston
- Haverhill
- Rochester Hills
- New York
- Staten Island
- Salem
- Allentown
- Arlington
- Austin
- Woodstock
- Richmond
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Otsuka Pharmaceutical Development & Commercialization, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Brexpiprazole.
Who was this study for?
Listed age limits: 18 years to 65 years.
